Research
Hormonal
Semaglutide is effective for weight loss in obese or overweight patients.
Semaglutide can be considered as a treatment option for weight management in obese or overweight patients.
StrongSupportsmedium confidence
meta-analyses of randomized controlled trials (RCTs) of semaglutide in patients with T2DM have shown benefits of the drug on glycaemic control and weight loss.
Why this rating
Based on meta-analysis of randomized controlled trials.
Source
Once‐weekly semaglutide for obesity or overweight: A systematic review and meta‐analysis
Ke He et al. · Diabetes Obesity and Metabolism · 2021
DOI 10.1111/dom.14612
Meta-analysisCited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →